Published • loading... • Updated
Prostate Cancer Screening: Final Guidance Recommends Against Testing All Men
The committee said screening 2,000 men a year could help only some BRCA2 carriers, while population screening is likely to do more harm than good.
- On Thursday, the UK National Screening Committee published final guidance limiting prostate cancer screening to men aged 45–61 with BRCA2 variants and specific family cancer histories.
- Attempting to detect prostate cancer via the prostate-specific antigen test is 'likely to cause more harm than good,' the UKNSC advised, citing risks of overdiagnosis, incontinence, and erectile dysfunction in men not needing treatment.
- Recent studies indicated the risk is mainly from BRCA2, not BRCA1, with 21–35 of every 100 BRCA2 carriers developing prostate cancer before age 80, prompting exclusion of BRCA1 carriers from the final guidance.
- Prostate Cancer UK expressed disappointment, noting the UK loses more than 12,000 men annually, while Health Secretary James Murray will give 'full and careful consideration' to the recommendation.
- The UKNSC will continue monitoring data from the Transform trial, as current evidence does not support screening other groups, including black men, due to insufficient proof of benefit.
Insights by Ground AI
17 Articles
17 Articles
Coverage Details
Total News Sources17
Leaning Left2Leaning Right1Center5Last UpdatedBias Distribution63% Center
Bias Distribution
- 63% of the sources are Center
63% Center
L 25%
C 63%
12%
Factuality
To view factuality data please Upgrade to Premium
